| __timestamp | Bristol-Myers Squibb Company | Eli Lilly and Company |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 6620800000 |
| Thursday, January 1, 2015 | 5001000000 | 6533000000 |
| Friday, January 1, 2016 | 5002000000 | 6452000000 |
| Sunday, January 1, 2017 | 4849000000 | 6588100000 |
| Monday, January 1, 2018 | 4551000000 | 5975100000 |
| Tuesday, January 1, 2019 | 4871000000 | 6213800000 |
| Wednesday, January 1, 2020 | 7661000000 | 6121200000 |
| Friday, January 1, 2021 | 7690000000 | 6431600000 |
| Saturday, January 1, 2022 | 7814000000 | 6440400000 |
| Sunday, January 1, 2023 | 7772000000 | 6941200000 |
| Monday, January 1, 2024 | 8414000000 | 8593800000 |
Igniting the spark of knowledge
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Eli Lilly and Company and Bristol-Myers Squibb Company have demonstrated contrasting trends in their SG&A efficiency. From 2014 to 2023, Eli Lilly consistently maintained higher SG&A expenses, peaking at approximately $6.94 billion in 2023. In contrast, Bristol-Myers Squibb's SG&A expenses fluctuated more dramatically, with a notable increase of nearly 70% from 2018 to 2020, reaching a high of $7.81 billion in 2022. This divergence highlights Eli Lilly's steady approach versus Bristol-Myers Squibb's more variable strategy. Understanding these trends provides valuable insights into each company's operational focus and strategic priorities, offering a window into their financial health and market positioning.
Eli Lilly and Company and Novo Nordisk A/S: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Merck & Co., Inc.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Opthea Limited
Comparing SG&A Expenses: Eli Lilly and Company vs CRISPR Therapeutics AG Trends and Insights
Eli Lilly and Company vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Eli Lilly and Company vs Agios Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Xencor, Inc.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.